- Home
- WSBF vs DSGN Comparison
WSBF vs DSGN Comparison
Compare WSBF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- DSGN
- Stock Information
- Founded
- WSBF 1921
- DSGN 2017
- Country
- WSBF United States
- DSGN United States
- Employees
- WSBF N/A
- DSGN N/A
- Industry
- WSBF Savings Institutions
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- DSGN Health Care
- Exchange
- WSBF Nasdaq
- DSGN Nasdaq
- Market Cap
- WSBF 240.7M
- DSGN 224.8M
- IPO Year
- WSBF N/A
- DSGN 2021
- Fundamental
- Price
- WSBF $12.92
- DSGN $3.73
- Analyst Decision
- WSBF
- DSGN Hold
- Analyst Count
- WSBF 0
- DSGN 1
- Target Price
- WSBF N/A
- DSGN $4.00
- AVG Volume (30 Days)
- WSBF 49.7K
- DSGN 91.9K
- Earning Date
- WSBF 07-24-2025
- DSGN 05-07-2025
- Dividend Yield
- WSBF 4.63%
- DSGN N/A
- EPS Growth
- WSBF 95.86
- DSGN N/A
- EPS
- WSBF 1.02
- DSGN N/A
- Revenue
- WSBF $133,551,000.00
- DSGN N/A
- Revenue This Year
- WSBF N/A
- DSGN N/A
- Revenue Next Year
- WSBF N/A
- DSGN N/A
- P/E Ratio
- WSBF $12.70
- DSGN N/A
- Revenue Growth
- WSBF 1.81
- DSGN N/A
- 52 Week Low
- WSBF $11.61
- DSGN $2.60
- 52 Week High
- WSBF $16.86
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- WSBF 56.87
- DSGN 48.52
- Support Level
- WSBF $12.49
- DSGN $3.31
- Resistance Level
- WSBF $12.90
- DSGN $4.13
- Average True Range (ATR)
- WSBF 0.26
- DSGN 0.31
- MACD
- WSBF 0.04
- DSGN 0.04
- Stochastic Oscillator
- WSBF 63.53
- DSGN 61.27
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.